Testing effectiveness (Phase 2)Study completedNCT02625961
What this trial is testing
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Who this might be right for
Bladder Cancer
Merck Sharp & Dohme LLC 296